Export file:

Format

  • RIS(for EndNote,Reference Manager,ProCite)
  • BibTex
  • Text

Content

  • Citation Only
  • Citation and Abstract

CSB modulates the competition between HIF-1 and p53 upon hypoxia

1 National Laboratory of Solid State Microstructures, Department of Physics, and Collaborative Innovation Center of Advanced Microstructures, Nanjing University, Nanjing 210093, P.R. China
2 Kuang Yaming Honors School, Nanjing University, Nanjing 210023, P.R. China
3 Institute for Brain Sciences, Nanjing University, Nanjing 210093, P.R. China

Special Issues: Computational models in life sciences

Both hypoxia-inducible factor-1 (HIF-1) and tumor suppressor p53 are involved in the cellular response to hypoxia. It has been reported that HIF-1α induces cockayne syndrome B (CSB) to compete with p53 for limited p300. We developed a network model to clarify how the interplay between HIF-1 and p53 modulates cellular output in the presence of CSB. Our results revealed that HIF-1α is progressively activated depending on the severity of hypoxia. Activated HIF-1α promotes its own activation by inducing CSB to dissociate p300 from p53 under moderate hypoxia; in severe hypoxia, p53 accumulates remarkably due to ATR-dependent phosphorylation and wins the competition for p300. As a result, HIF-1α induces PFKL and VEGF to facilitate cellular adaptation to mild and moderate hypoxia respectively, while p53 is activated to induce apoptosis under severe hypoxia. This work may advance the understanding of the modulation of the interplay between HIF-1 and p53 in the hypoxic response.
  Figure/Table
  Supplementary
  Article Metrics

Keywords network model; HIF-1α; p53; CSB; hypoxia

Citation: Xiao-Wei Ye, Xiao-Peng Zhang, Feng Liu. CSB modulates the competition between HIF-1 and p53 upon hypoxia. Mathematical Biosciences and Engineering, 2019, 16(5): 5247-5262. doi: 10.3934/mbe.2019262

References

  • 1. G. L. Semenza, Hypoxia-inducible factors in physiology and medicine, Cell, 148(2012), 399–408.
  • 2. C. J. Schofield and P. J. Ratcliffe, Oxygen sensing by HIF hydroxylases, Nat. Rev. Mol. Cell Biol., 5 (2004), 343–354.
  • 3. M. Ivan, K. Kondo, H. F. Yang, et al., HIF targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing, Science, 292 (2001), 464–468.
  • 4. D. Lando, D. J. Peet, J. J. Gorman, et al., FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor, Genes Dev., 16 (2002), 1466–1471.
  • 5. F. Dayan, D. Roux, M. C. Brahimi-Horn, et al., The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor-alpha, Cancer Res., 66 (2006), 3688–3698.
  • 6. K. T. Bieging, S. S. Mello and L. D. Attardi, Unravelling mechanisms of p53-mediated tumour suppression, Nat. Rev. Cancer, 14 (2014), 359–370.
  • 7. X.-P. Zhang, F. Liu, Z. Cheng, et al., Cell fate decision mediated by p53 pulses, Proc. Natl. Acad. Sci. USA, 106 (2009), 12245–12250.
  • 8. X.-P. Zhang, F. Liu and W. Wang, Two-phase dynamics of p53 in the DNA damage response, Proc. Natl. Acad. Sci. USA, 108 (2011), 8990–8995.
  • 9. C. H. Zhou, X. P. Zhang, F. Liu, et al., Modeling the interplay between the HIF-1 and p53 pathways in hypoxia, Sci. Rep., 5 (2015), 13834.
  • 10. S. Filippi, P. Latini, M. Frontini, et al., CSB protein is (a direct target of HIF-1 and) a critical mediator of the hypoxic response, EMBO J., 27 (2008), 2545–2556.
  • 11. T. Schmid, J. Zhou, R. Kohl, et al., p300 relieves p53-evoked transcriptional repression of hypoxia-inducible factor-1 (HIF-1), Biochem. J., 380 (2004), 289–295.
  • 12. M. Frontini and L. Proietti-De-Santis, Cockayne syndrome B protein (CSB) linking p53, HIF-1 and p300 to robustness, lifespan, cancer and cell fate decisions, Cell Cycle, 8 (2009), 693–696.
  • 13. R. Vélez-Cruz and J. M. Egly, Cockayne syndrome group B (CSB) protein: At the crossroads of transcriptional networks, Mech. Ageing Dev., 134 (2013), 234–242.
  • 14. W. G. An, M. Kanekal, M. C. Simon, et al., Stabilization of wild-type p53 by hypoxia-inducible factor 1α, Nature, 392 (1998), 405–408.
  • 15. D. Chen, M. Li, J. Luo, et al., Direct interactions between HIF-1α and Mdm2 modulate p53 function, J. Biol. Chem., 278 (2003), 13595–13598.
  • 16. E. M. Hammond, N. C. Denko, M. J. Dorie, et al., Hypoxia links ATR and p53 through replication arrest, Mol. Cell Biol., 22 (2002), 1834–1843.
  • 17. A. Sermeus and C. Michiels, Reciprocal influence of the p53 and the hypoxic pathways, Cell Death Dis., 2 (2011), e164.
  • 18. J. S. Fridman and S. W. Lowe, Control of apoptosis by p53, Oncogene, 22 (2003), 9030–9040.
  • 19. Z. Fábián, C. T. Taylor and L. K. Nguyen, Understanding complexity in the HIF signaling pathway using systems biology and mathematical modeling, J. Mol. Med., 94 (2016), 377–390.
  • 20. A. A. Qutub and A. S. Popel, A computational model of intracellular oxygen sensing by hypoxia-inducible factor HIF1α, J. Cell Sci., 119 (2006), 3467–3480.
  • 21. L. K. Nguyen, M. A. S. Cavadas, C. C. Scholz, et al., A dynamic model of the hypoxia-inducible factor 1α (HIF-1α) network, J. Cell Sci., 126 (2013), 1454–1463.
  • 22. J. Bagnall, J. Leedale, S. E. Taylor, et al., Tight control of hypoxia-inducible factor-α transient dynamics is essential for cell survival in hypoxia, J. Biol. Chem., 289 (2014), 5549–5564.
  • 23. P. Koivunen, M. Hirsilä, V. Günzler, et al., Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases, J. Biol. Chem., 279 (2004), 9899–9904.
  • 24. Y. Tian, K. K. Yeoh, M. K. Lee, et al., Differential sensitivity of HIF hydroxylation sites to hypoxia and hydroxylase inhibitors, J. Biol. Chem., 286 (2011), 13041–13051.
  • 25. R. Ravi, B. Mookerjee, Z. M. Bhujwalla, et al., Regulation of tumor angiogenesis by p53-induced ubiquitin-mediated degradation of hypoxia-inducible factor-1α, Genes Dev., 14 (2000), 34–44.
  • 26. S. J. Lee, C. J. Lim, J. K. Min, et al., Protein phosphatase 1 nuclear targeting subunit is a hypoxia inducible gene: its role in post-translational modification of p53 and MDM2, Cell Death. Differ., 14 (2007), 1106–1116.
  • 27. G. L. Semenza, P. H. Roth, H. M. Fang, et al., Transcriptional regulation of genes encoding glycolytic-enzymes by hypoxia-inducible factor-1, J. Biol. Chem., 269 (1994), 23757–23763.
  • 28. J. A. Forsythe, B. H. Jiang, N. V. Iyer, et al., Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1, Mol. Cell Biol., 16 (1996), 4604–4613.
  • 29. S. Z. Liu, B. Shiotani, M. Lahiri, et al., ATR autophosphorylation as a molecular switch for checkpoint activation, Mol. Cell, 43 (2011), 192–202.
  • 30. B. D. Manning and L. C. Cantley, AKT/PKB signaling: Navigating downstream, Cell, 129 (2007), 1261–1274.
  • 31. A. J. Levine and M. Oren, The first 30 years of p53: growing ever more complex, Nat. Rev. Cancer, 9 (2009), 749–758.
  • 32. Y. Yu, G. Wang, R. Simha, et al., Pathway switching explains the sharp response characteristic of hypoxia response network, PLoS Comput. Biol., 3 (2007), e171.
  • 33. R. L. Weinberg, D. B. Veprintsev, M. Bycroft, et al., Comparative binding of p53 to its promoter and DNA recognition elements, J. Mol. Biol., 348 (2005), 589–596.
  • 34. M. Y. Koh and G. Powis, Passing the baton: the HIF switch, Trends Biochem. Sci., 37 (2012), 364–372.
  • 35. M. Caputo, M. Frontini, R. Velez-Cruz, et al., The CSB repair factor is overexpressed in cancer cells, increases apoptotic resistance, and promotes tumor growth, DNA Rep., 12 (2013), 293–299.
  • 36. J. A. Bertout, S. A. Patel and M. C. Simon, The impact of O2 availability on human cancer, Nat. Rev. Cancer, 8 (2008), 967–975.
  • 37. Y. M. Lee, J. H. Lim, Y. S. Chun, et al., Nutlin-3, an Hdm2 antagonist, inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated inactivation of HIF-1α, Carcinogenesis, 30 (2009), 1768–1775.
  • 38. S. Bhattacharya, C. L. Michels, M. K. Leung, et al., Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1, Genes Dev., 13 (1999), 64–75.
  • 39. D. H. Shin, S. H. Li, Y. S. Chun, et al., CITED2 mediates the paradoxical responses of HIF-1α to proteasome inhibition, Oncogene, 27 (2008), 1939–1944.
  • 40. K. Mattes, G. Berger, M. Geugien, et al., CITED2 affects leukemic cell survival by interfering with p53 activation, Cell Death Dis., 8 (2017), e3132.

 

Reader Comments

your name: *   your email: *  

© 2019 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution Licese (http://creativecommons.org/licenses/by/4.0)

Download full text in PDF

Export Citation

Copyright © AIMS Press All Rights Reserved